Recent Updates
Recently added Catalysts
SMMT Positive Sentiment

Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients

Tuesday, September 15, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Summit Therapeutics Inc. presented updated overall survival results from the Phase III HARMONi trial at the WCLC 2026. The data highlights the effectiveness of ivonescimab combined with chemotherapy in both Western and Asian patients. This investigational bispecific antibody shows promise as a first-in-class treatment option.

Market Sentiment Analysis

POSITIVE FACTORS

  • Updated overall survival results show consistency across populations.
  • Ivonescimab is a potential first-in-class bispecific antibody.
  • Presentation at a prestigious international conference enhances visibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+27%
120-day peak, hindsight
Typical move
36.9%
average across 3 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
Ivonescimab
Phase 3 · Non-Small Cell Lung Cancer

Full Press Release Details

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) announced that updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab were presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC 2026) in Seoul, Republic of Korea. As Summit previously announced on July 22, 2026, ivonescimab plus plat

Frequently Asked Questions

What is ivonescimab?

Ivonescimab is a novel bispecific antibody being investigated for cancer treatment.

Where were the updated HARMONi results presented?

The results were presented at the WCLC 2026 in Seoul, South Korea.

What does the HARMONi trial focus on?

The HARMONi trial focuses on the overall survival of patients receiving ivonescimab plus chemotherapy.

What populations were included in the HARMONi results?

The results included both Western and Asian patient populations.

ShareAdd on Google
Tags: SMMT Viatris Investor Conferences Healthcare Summit Therapeutics HARMONi trial ivonescimab WCLC 2026 bispecific antibody
Last updated: Sep 15, 2026

Biotech snapshot

Cash runway
$691M liquidity · $47M/mo burn
~13 mo
Low dilution risk
Lead asset
IvonescimabPhase 3
Non-Small Cell Lung Cancer →

Catalyst track record

+27%
best trade around SMMT's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for SMMT.

See every catalyst's timing & PoA →